Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 11/20 | 0.61 |
| ▸ | MAOB | P27338 | 11/20 | 0.61 |
| ▸ | PRKCI | P41743 | 1/20 | 0.61 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2585151 | 0.96 | MAOA (0.59) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL192610 | 0.88 | CASP1 (0.59) | MAOAMAOBPRKCIHSD17B1GRM5 | |
| SCHEMBL29726050 | 0.88 | CASP1 (0.59) | MAOAMAOBPRKCIHSD17B1GRM5 | |
| SCHEMBL7506302 | 0.85 | HSD17B1 (0.71) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL7507475 | 0.85 | HSD17B1 (0.56) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL769238 | 0.84 | MAOA (0.53) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL29446042 | 0.84 | MAOA (0.53) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| Hydrochloric Acid SCHEMBL9827967 | 0.82 | MAOA (0.48) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL17362038 | 0.81 | MAOA (0.53) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL4428197 | 0.81 | PARP10 (0.61) | MAOAMAOBPRKCIHSD17B1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 349 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115108928-B | Nitrogen mustard-tetralone derivative, preparation method and application thereof | 广东海洋大学 | 2024-06-11 | — | — | CN | claimed |
| CN-116670127-A | EGFR inhibitors and compositions and uses thereof | 贝达药业股份有限公司 | 2023-08-29 | — | — | CN | claimed |
| EP-3019141-B1 | HARDENABLE DENTAL COMPOSITION CONTAINING A MIXTURE OF AGGLOMERATED AND AGGREGATED NANOPARTICLES, KIT OF PARTS AND USE THEREOF | 3M INNOVATIVE PROPERTIES CO (US) | 2022-08-31 | — | — | EP | claimed |
| EP-4743445-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS DNA POLYMERASE THETA INHIBITORS FOR THE PREVENTION OR TREATMENT OF CANCER | Daewoong Pharmaceutical Co., Ltd. (KR) | 2026-05-20 | — | — | EP | disclosed |
| CN-118026958-B | 3, 4-Dihydro-1 (2H) -naphthalenone derivative, preparation method and application thereof | 滨州医学院 | 2026-05-12 | — | — | CN | disclosed |
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4688788-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | Pfizer Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | EIKONIZO THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| CN-115724799-B | Potassium channel regulator, composition and application | 纽欧申医药(上海)有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-12281127-B2 | Pyrido[4,3-d]pyrimidine compounds | PFIZER INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-12226405-B2 | Compounds and compositions for inhibiting the activity of HIF2-alpha and their methods of use | NOVARTIS AG (CH) | 2025-02-18 | — | — | US | disclosed |
| WO-1990007495-A1 | SUBSTITUTED SEMICARBAZONE ARTHROPODICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-07-12 | — | — | WO | disclosed |
| EP-0377304-A2 | Substituted semicarbazone arthropodicides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-07-11 | — | — | EP | disclosed |
| EP-0325963-A1 | 1-Aminomethyl-1,2,3,4-tetrahydronaphthalenes and -indanes | ABBOTT LABORATORIES (US) | 1989-08-02 | — | — | EP | disclosed |
| WO-1989006645-A1 | 1-AMINOMETHYL-1,2,3,4-TETRAHYDRONAPHTHALENES | ABBOTT LABORATORIES (US) | 1989-07-27 | — | — | WO | disclosed |
| US-4473586-A | Aminoalkyl dihydronaphthalenes | ABBOTT LABORATORIES (US) | 1984-09-25 | — | — | US | disclosed |
| US-4065569-A | Use of 2-imidazolines as hypoglycemic agents | SCHERING CORPORATION (US) | 1977-12-27 | — | — | US | disclosed |
| US-4051248-A | CENTRAL NERVOUS SYSTEM DEPRESSANTS, NEUROLEPTIC AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1977-09-27 | — | — | US | disclosed |
| US-3992403-A | 2-Imidazolines and their use as hypoglycemic agents | SCHERING CORPORATION (US) | 1976-11-16 | — | — | US | disclosed |
| US-3985731-A | MICROBIOCIDES, MOTOR ACTIVITY INDUCERS, CNS STIMULANTS | E. R. SQUIBB & SONS, INC. (US) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12226405-B2 | Compounds and compositions for inhibiting the activity of HIF2-alpha and their methods of use | HIF1AN, HIF1A, EGLN2 | MAOA 1877/4885MAOB 1081/4885PRKCI 668/4885 |
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC3, HDAC1 | MAOA 155/4885MAOB 106/4885PRKCI 3996/4885 |
| US-12281127-B2 | Pyrido[4,3-d]pyrimidine compounds | DPYD, PNPO, TYMP | MAOA 813/4885MAOB 294/4885PRKCI 2841/4885 |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | MAOA 545/4885MAOB 828/4885PRKCI 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.